Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. United Therapeutics Corporation
  6. Summary
    UTHR   US91307C1027

UNITED THERAPEUTICS CORPORATION

(UTHR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
184.32(c) 186.36(c) 192.27(c) 190.66(c) 191.01(c) Last
632 485 279 657 437 619 226 842 197 940 Volume
-1.47% +1.11% +3.17% -0.84% +0.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 672 M - -
Net income 2021 524 M - -
Net cash position 2021 509 M - -
P/E ratio 2021 16,8x
Yield 2021 -
Sales 2022 1 868 M - -
Net income 2022 734 M - -
Net cash position 2022 1 153 M - -
P/E ratio 2022 11,7x
Yield 2022 -
Capitalization 8 575 M 8 575 M -
EV / Sales 2021 4,82x
EV / Sales 2022 3,97x
Nbr of Employees 950
Free-Float 60,7%
More Financials
Company
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil)... 
Read more
More about the company
Ratings of United Therapeutics Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about UNITED THERAPEUTICS CORPORATION
10/21INSIDER SELL : United Therapeutics
MT
10/21United Therapeutics Corporation Details New Data Presented at Chest Annual Meeting 2021
CI
10/18MannKind Corporation and United Therapeutics Corporation Enter into an Amendment to the..
CI
10/18Today on Wall Street: This is the real test
10/18UNITED THERAPEUTICS : U.S. FDA declines to approve United-MannKind's lung disease therapy
RE
10/18UNITED THERAPEUTICS : Says FDA Letter Cites Single Deficiency in Hypertension Drug Tyvaso ..
MT
10/18UNITED THERAPEUTICS : Provides an Update on the Progress of the Tyvaso DPI™ New Drug..
PU
10/18UNITED THERAPEUTICS : U.S. FDA declines to approve United Therapeutics' lung disease drug
RE
10/18UNITED THERAPEUTICS CORP : Other Events (form 8-K)
AQ
10/18UNITED THERAPEUTICS : Provides an Update on the Progress of the Tyvaso DPI™ New Drug..
PR
10/18United Therapeutics Corporation Provides an Update on the Progress of the Tyvaso DPI™ N..
CI
10/18United Therapeutics New Drug Application Declined Pending Inspection Issue
DJ
10/11LIQUIDIA : Receives Favorable Ruling in Inter Partes Review against United Therapeutics Pa..
AQ
10/11United Therapeutics to Present New Data At Chest Annual Meeting 2021
CI
10/11LIQUIDIA : Gets Favorable US Patent Panel Ruling in Inter Partes Review Against United The..
MT
More news
News in other languages on UNITED THERAPEUTICS CORPORATION
10/21VENTE D'INITIÉS : United Therapeutics
10/18MÄRKTE USA/Börse hakt schwache Daten ab - Technologiewerte gesucht
10/18MÄRKTE USA/Erholt von Anfangsverlusten - Technologiewerte vorne
10/11Liquidia obtient une décision favorable du panel des brevets américains dans le cadre d..
09/15CAE et BETA Technologies détaillent leur partenariat stratégique pour le programme de f..
More news
Analyst Recommendations on UNITED THERAPEUTICS CORPORATION
More recommendations
Stock Trading Strategies
UNITED THERAPEUTICS CORPORATION - 2020
The technical configuration is positive
BUY
More Stock Trading Analysis
Chart UNITED THERAPEUTICS CORPORATION
Duration : Period :
United Therapeutics Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UNITED THERAPEUTICS CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 191,01 $
Average target price 231,89 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
Martine A. Rothblatt Chairman & Chief Executive Officer
Michael Ian Benkowitz President & Chief Operating Officer
James Christopher Edgemond Chief Financial Officer & Treasurer
Raymond C. Kurzweil Independent Director
Louis Wade Sullivan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
UNITED THERAPEUTICS CORPORATION25.84%8 575
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455